Vasculitis and Glomerulonephritis Center, Division of Nephrology, Massachusetts General Hospital, Boston, MA.
Department of Nephrology, Lokmanya Tilak Municipal General Hospital, Mumbai, India.
Adv Chronic Kidney Dis. 2022 Mar;29(2):116-126.e1. doi: 10.1053/j.ackd.2022.02.009.
Paraneoplastic glomerular diseases (GNs) are rare manifestations in patients with underlying hematologic and solid organ malignancies and can occur before or after the detection of cancer. In the absence of established algorithms for investigation and reliable tests, they remain difficult to diagnose. Given the heterogeneity and infrequency of cases, the pathogenesis of most paraneoplastic GNs is poorly understood. Most of our recent understanding of paraneoplastic GNs has emerged from the discovery of target antigens in membranous nephropathy such as thrombospondin type-1 domain-containing protein 7A and neural epidermal growth factor-like 1 protein that appear to be promising in differentiating a primary vs paraneoplastic cause of membranous nephropathy. Treatment of paraneoplastic GNs is usually directed at the underlying malignancy. This review will focus on the epidemiology, pathogenesis, and diagnosis of paraneoplastic glomerular processes.
副肿瘤性肾小球疾病 (GNs) 是潜在血液系统和实体器官恶性肿瘤患者的罕见表现,可发生在癌症检测之前或之后。在缺乏既定的调查算法和可靠的检测方法的情况下,这些疾病仍然难以诊断。鉴于其异质性和罕见性,大多数副肿瘤性 GNs 的发病机制仍不清楚。我们最近对副肿瘤性 GNs 的了解主要来自于在膜性肾病中发现的靶抗原,例如血小板反应蛋白 1 型结构域蛋白 7A 和神经表皮生长因子样 1 蛋白,这些抗原似乎在区分原发性和副肿瘤性膜性肾病方面很有前景。副肿瘤性 GNs 的治疗通常针对潜在的恶性肿瘤。本文将重点讨论副肿瘤性肾小球病变的流行病学、发病机制和诊断。